keyword
MENU ▼
Read by QxMD icon Read
search

FIB-4

keyword
https://www.readbyqxmd.com/read/28425454/association-of-serum-autotaxin-levels-with-liver-fibrosis-in-patients-with-chronic-hepatitis-c
#1
Tomoo Yamazaki, Satoru Joshita, Takeji Umemura, Yoko Usami, Ayumi Sugiura, Naoyuki Fujimori, Soichiro Shibata, Yuki Ichikawa, Michiharu Komatsu, Akihiro Matsumoto, Koji Igarashi, Eiji Tanaka
Metabolized by liver sinusoidal endothelial cells, autotaxin (ATX) is a secreted enzyme considered to be associated with liver damage. We sought to clarify the diagnostic ability of ATX for liver fibrosis in 593 biopsy-confirmed hepatitis C virus (HCV)-infected patients. The diagnostic accuracy of ATX was compared with clinical parameters and the established fibrosis biomarkers Wisteria floribunda agglutinin-positive Mac-2-binding protein, FIB-4 index, AST-to-platelet ratio, and Forn's index. Median ATX levels were consistently higher in female controls and patients than in their male counterparts (P < 0...
April 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28425016/a-simple-bedside-blood-test-fibrofast-fib-5-is-superior-to-fib-4-index-for-the-differentiation-between-non-significant-and-significant-fibrosis-in-patients-with-chronic-hepatitis-c
#2
G Shiha, S Seif, A Eldesoky, M Elbasiony, R Soliman, A Metwally, K Zalata, N Mikhail
INTRODUCTION: A simple non-invasive score (Fibrofast, FIB-5) was developed using five routine laboratory tests (ALT, AST, alkaline phosphatase, albumin and platelets count) for the detection of significant hepatic fibrosis in patients with chronic hepatitis C. The FIB-4 index is a non-invasive test for the assessment of liver fibrosis, and a score of ≤1.45 enables the correct identification of patients who have non-significant (F0-1) from significant fibrosis (F2-4), and could avoid liver biopsy...
April 19, 2017: Hepatology International
https://www.readbyqxmd.com/read/28422310/adult-onset-cystic-fibrosis-liver-disease-diagnosis-and-characterization-of-an-underappreciated-entity
#3
Christopher Koh, Sasan Sakiani, Pallavi Surana, Xiongce Zhao, Jason Eccleston, David E Kleiner, David Herion, T Jake Liang, Jay H Hoofnagle, Milica Chernick, Theo Heller
BACKGROUND & AIMS: Cystic fibrosis liver disease (CFLD), a leading cause of death in cystic fibrosis (CF), is mostly described in pediatric populations. Adult-onset CFLD lacks sufficient characterization and diagnostic tools. METHODS: A cohort of CF patients without CFLD during childhood were followed for up to 38 years with serologic testing, imaging, and noninvasive fibrosis markers. Historical CFLD diagnostic criteria were compared with a newly proposed CFLD criteria...
April 19, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28415736/the-gamma-glutamyl-transpeptidase-to-platelet-ratio-for-non-invasive-assessment-of-liver-fibrosis-in-patients-with-chronic-hepatitis-b-and-non-alcoholic-fatty-liver-disease
#4
Qiang Li, Chuan Lu, Weixia Li, Yuxian Huang, Liang Chen
BACKGROUND/AIM: The gamma-glutamyl transpeptidase-to-platelet ratio (GPR) is a novel serum model, which was reported more accurate than aspartate transaminase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) for diagnosing significant fibrosis and cirrhosis in HBV mono-infection in West Africa. We aimed to evaluate the diagnostic performance of GPR for liver fibrosis in patients with chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD)...
March 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28414057/non-invasive-assessment-of-liver-fibrosis-in-patients-with-hbv-related-chronic-liver-disease-undergoing-antiviral-treatment-a-preliminary-study
#5
Cristina Stasi, Elena Salomoni, Umberto Arena, Giampaolo Corti, Paolo Montalto, Filippo Bartalesi, Fabio Marra, Giacomo Laffi, Stefano Milani, Anna Linda Zignego, Massimo Pinzani
In chronic hepatitis B (CHB) patients, fibrosis assessment during antiviral treatment is a key step in the clinical management. Aim of this study was to evaluate the performance of elastography in assessing fibrosis stage in CHB before and after two years of nucleoside/nucleotide analogues (NUC) treatment in comparison with indirect serum markers. CHB diagnosis was made according to standard criteria. A clinical and virological evaluation was performed at baseline and again at 3, 6, 9, 12 18, and 24 months during treatment...
April 13, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28409147/incidence-and-predictors-of-advanced-liver-fibrosis-by-a-validated-serum-biomarker-in-liver-transplant-recipients
#6
Mamatha Bhat, Kathleen C Rollet-Kurhajec, Aparna Bhat, Amanda Farag, Marc Deschenes, Philip Wong, Peter Ghali, Giada Sebastiani
Background and Aims. Serum fibrosis biomarkers have shown good accuracy in the liver transplant (LT) population. We employed a simple serum biomarker to elucidate incidence and predictors of advanced fibrosis after LT over a long follow-up period. Methods. We included 440 consecutive patients who underwent LT between 1991 and 2013. Advanced liver fibrosis was defined as FIB-4 > 3.25 beyond 12 months after LT. Results. Over 2030.5 person-years (PY) of follow-up, 189 (43%) developed FIB-4 > 3.25, accounting for an incidence of 9...
2017: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28387018/transient-elastography-alone-and-in-combination-with-fibrotest-%C3%A2-for-the-diagnosis-of-hepatic-fibrosis-in-alcoholic-liver-disease
#7
Cosmin Sebastian Voican, Alexandre Louvet, Jean-Baptiste Trabut, Micheline Njiké-Nakseu, Sébastien Dharancy, Andrea Sanchez, Marion Corouge, Karima Lamouri, Amandine Lebrun, Axel Balian, Sophie Prévot, Mounia Lachgar, Sophie Maitre, Hélène Agostini, Philippe Mathurin, Gabriel Perlemuter, Sylvie Naveau
BACKGROUND&AIMS: The reliability of transient elastography (TE) to assess liver fibrosis is insufficiently validated in alcoholic liver disease (ALD). We aimed to validate the diagnostic utility of TE for liver fibrosis in patients with excessive alcohol consumption and evaluate whether Fibrotest(®) adds diagnostic value relative to or in combination with TE. METHODS: We conducted a multicenter prospective study on a total of 217 heavy drinkers with high serum aminotransferase levels...
April 7, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28369305/comparing-child-pugh-meld-and-fib-4-to-predict-clinical-outcomes-in-hcv-infected-persons-results-from-erchives
#8
Adeel A Butt, Yanjie Ren, Vincent Lo Re, Tamar Taddei, David Kaplan
Background: Identifying HCV+ persons at high risk of early complications can help prioritize treatment decisions. We conducted this study to compare Child-Turcotte-Pugh (CP), MELD and FIB-4 scores for predicting clinical outcomes and to identify those at low risk of complications. Methods: Within Electronically Retrieved Cohort of HCV-Infected Veterans, we identified HCV+ persons and excluded those with HIV+, HBsAg+, prevalent hepatic decompensation (HD), hepatocellular carcinoma (HCC) and those treated for HCV...
March 22, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28357031/concordance-of-non-invasive-mechanical-and-serum-tests-for-liver-fibrosis-evaluation-in-chronic-hepatitis-c
#9
Denise C Paranaguá-Vezozzo, Adriana Andrade, Daniel F C Mazo, Vinicius Nunes, Ana L Guedes, Taisa G Ragazzo, Renata Moutinho, Lucas S Nacif, Suzane K Ono, Venâncio A F Alves, Flair J Carrilho
AIM: To determine the sensitivity and specificity of liver stiffness measurement (LSM) and serum markers (SM) for liver fibrosis evaluation in chronic hepatitis C. METHODS: Between 2012 and 2014, 81 consecutive hepatitis C virus (HCV) patients had METAVIR score from liver biopsy compared with concurrent results from LSM [transient elastography (TE) [FibroScan(®)/ARFI technology (Virtual Touch(®))] and SM [FIB-4/aspartate aminotransferase-to-platelet ratio index (APRI)]...
March 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28335783/svr-rates-of-hcv-infected-population-under-peg-ifn-%C3%AE-r-treatment-in-northwest-china
#10
Yanhua Li, Jiuping Wang, Juan Wang, Yunfeng Xiao, Bin Xu, Hongwei Li, Liu Yang, Xiaoke Hao, Yueyun Ma
BACKGROUND: Chronic HCV Patients taking PEG-IFN-α/R from different ethnic groups have different probabilities of reaching a sustained viral response (SVR). There are many influence factors, such as HCV genotype, IL-28B single-nucleotide polymorphisms (SNP), Fibrosis 4 index (FIB-4), and aspartate aminotransferase-to-platelet ratio index (APRI) score. But the baseline factors in relation to treatment outcome was still not much clear. METHODS: We evaluated data from 231 chronic HCV patients with or without liver fibrosis and their antiviral efficacy after treatment with pegylated interferon plus ribavirin (PEG-IFN-α/R) for 24-48 weeks...
March 23, 2017: Virology Journal
https://www.readbyqxmd.com/read/28328813/evaluation-of-apri-and-fib-4-for-noninvasive-assessment-of-significant-fibrosis-and-cirrhosis-in-hbeag-negative-chb-patients-with-alt%C3%A2-%C3%A2-%C3%A2-2-uln-a-retrospective-cohort-study
#11
Qiang Li, Xiaojing Ren, Chuan Lu, Weixia Li, Yuxian Huang, Liang Chen
To evaluate the performance of aspartate transaminase-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) to predict significant fibrosis and cirrhosis in hepatitis B virus e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients with alanine transaminase (ALT) ≤ twice the upper limit of normal (2 ULN).Histologic and laboratory data of 236 HBeAg-negative CHB patients with ALT ≤ 2 ULN were analyzed. Predicted fibrosis stage, based on established scales and cut-offs for APRI and FIB-4, was compared with METAVIR scores obtained from liver biopsy...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28323868/-waiting-for-daas-a-retrospective-chart-review-of-patients-with-untreated-hepatitis-c-in-rwanda
#12
Neil Gupta, Jules Kabahizi, Constance Mukabatsinda, Timothy David Walker, Emmanuel Musabeyezu, Athanase Kiromera, Jennifer Ilo Van Nuil, Kevin Steiner, Joia Mukherjee, Sabin Nsanzimana, Aimable Mbituyumuremyi
BACKGROUND: Access to treatment for hepatitis C virus (HCV) in sub-Saharan Africa is extremely limited. With the advent of direct acting antivirals (DAAs), highly effective and easy-to-deliver oral regimens are now available on the global market. This study was conducted to understand the background and characteristics of a national cohort of patients with HCV infection enrolled in care and awaiting therapy with DAAs. METHODS AND FINDINGS: We conducted a retrospective chart review of all adult patients with confirmed HCV infection who were currently enrolled in care and treatment at the four existing hepatitis referral centers in Rwanda...
2017: PloS One
https://www.readbyqxmd.com/read/28322102/gamma-glutamyl-transpeptidase-to-platelet-ratio-index-is-a-good-noninvasive-biomarker-for-predicting-liver-fibrosis-in-chinese-chronic-hepatitis-b-patients
#13
Rong-Qi Wang, Qing-Shan Zhang, Su-Xian Zhao, Xue-Min Niu, Jing-Hua Du, Hui-Juan Du, Yue-Min Nan
Objective To evaluate whether gamma-glutamyl transpeptidase to platelet ratio index (GPRI) can diagnose the extent of liver fibrosis in Chinese patients with chronic hepatitis B (CHB) infection. Methods This prospective observational study used liver biopsy results as the gold standard to evaluate the ability of GPRI to predict hepatic fibrosis compared with two other markers, the aspartate aminotransferase (AST) to platelet ratio index (APRI) and fibrosis-4 score (FIB-4). The clinical and demographic factors that affected GPRI, independent of liver fibrosis, were assessed using multivariate linear regression analyses...
December 2016: Journal of International Medical Research
https://www.readbyqxmd.com/read/28299813/improvement-of-liver-stiffness-in-patients-with-hepatitis-c-virus-infection-who-received-direct-acting-antiviral-therapy-and-achieved-sustained-virological-response
#14
Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, Kazuyuki Mizuno, Yasuhiro Sone, Saki Kataoka, Shinichi Hashinokuchi
BACKGROUND AND AIM: There is insufficient research on whether direct-acting antiviral (DAA) therapy can improve liver fibrosis in patients with chronic hepatitis C virus (HCV). We evaluated sequential changes in liver stiffness using shear wave elastography (SWE) in patients with HCV who received DAA therapy. METHODS: A total of 210 patients with HCV who received daclatasvir and asunaprevir therapy and achieved sustained virological response (SVR) were analyzed...
March 15, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28298195/role-of-systemic-inflammation-scores-for-prediction-of-clinical-outcomes-in-patients-treated-with-atazanavir-not-boosted-by-ritonavir-in-the-italian-master-cohort
#15
Maria Concetta Postorino, Mattia Prosperi, Emanuele Focà, Eugenia Quiros-Roldan, Elisa Di Filippo, Franco Maggiolo, Alberto Borghetti, Nicoletta Ladisa, Massimo Di Pietro, Andrea Gori, Laura Sighinolfi, Angelo Pan, Nicola Mazzini, Carlo Torti
BACKGROUND: Atazanavir (ATV) not boosted by ritonavir (uATV) has been frequently used in the past for switching combination antiretroviral therapy (cART). However, the clinical outcomes and predictors of such strategy are unknown. METHODS: An observational study was carried out on the Italian MASTER, selecting HIV infected patients on cART switching to an uATV-containing regimen. Baseline was set as the last visit before uATV initiation. In the primary analysis, a composite clinical end-point was defined as the first occurring of any condition among: liver, cardiovascular, kidney, diabetes, non AIDS related cancer or death events...
March 15, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28297803/-correlation-of-liver-stiffness-measured-by-fibrotouch-and-fibroscan-with-ishak-fibrosis-score-in-patients-with-chronic-hepatitis-b
#16
G F Chen, J Ping, H T Gu, Z M Zhao, Y Zhou, F Xing, Y Y Tao, Y P Mu, P Liu, C H Liu
Objective: To investigate the correlation of liver stiffness measured by FibroTouch (FT) and FibroScan (FS) with Ishak fibrosis score in patients with chronic hepatitis B. Methods: A total of 313 patients with chronic hepatitis B who visited Department of Liver Cirrhosis in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from November 2014 to May 2016 were enrolled. All the patients underwent liver biopsy, and FT and FS were used to determine liver stiffness measurement (LSM)...
February 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/28288193/nonalcoholic-fatty-liver-disease-and-increased-risk-of-1-year-all-cause-and-cardiac-hospital-readmissions-in-elderly-patients-admitted-for-acute-heart-failure
#17
Filippo Valbusa, Stefano Bonapace, Davide Agnoletti, Luca Scala, Cristina Grillo, Pietro Arduini, Emanuela Turcato, Alessandro Mantovani, Giacomo Zoppini, Guido Arcaro, Christopher Byrne, Giovanni Targher
Nonalcoholic fatty liver disease (NAFLD) is an emerging risk factor for heart failure (HF). Although some progress has been made in improving survival among patients admitted for HF, the rates of hospital readmissions and the related costs continue to rise dramatically. We sought to examine whether NAFLD and its severity (diagnosed at hospital admission) was independently associated with a higher risk of 1-year all-cause and cardiac re-hospitalization in patients admitted for acute HF. We studied 212 elderly patients who were consecutively admitted with acute HF to the Hospital of Negrar (Verona) over a 1-year period...
2017: PloS One
https://www.readbyqxmd.com/read/28258705/daclatasvir-and-asunaprevir-treatment-in-patients-with-severe-liver-fibrosis-by-hcv-genotype-1b-infection-real-world-data
#18
Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Teiji Kuzuya, Yoji Ishizu, Tetsuya Ishikawa, Isao Nakano, Fumihiro Urano, Takashi Kumada, Kentaro Yoshioka, Hidemi Goto, Yoshiki Hirooka
BACKGROUNDS AND AIMS: In this study, we investigated the real-world data of the first approved interferon free regimen in Japan; daclatasvir as asunaprevir in chronic hepatitis C patients with severe fibrosis. PATIENTS AND METHODS: Among 924 patients registered in our multicenter study, 535 patients were defined as having severe fibrosis with Fib-4 index≧3.25, and were included in this study. We investigated anti-viral effect and factors associated with SVR12, and the additional effects on serum AFP and albumin levels by eradicating virus in patients who attained SVR were investigated...
March 4, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28247581/vap-score-as-a-novel-non-invasive-liver-fibrosis-model-in-patients-with-chronic-hepatitis-c
#19
Elham Ahmed Hassan, Abeer Sharaf El-Din Abd El-Rehim, Zain El-Abdeen Ahmed Sayed, Emad Farah Mohamed Kholef, Abeer Sabry, Noha Abd El-Rehim Abo Elhagag
AIM: Assessment of liver fibrosis in chronic hepatitis C (CHC) patients is necessary before antiviral treatment. This study aimed to evaluate the effectiveness of eight non-invasive models (aspartate aminotransferase [AST]/alanine transaminase ratio [AAR], AST/platelet ratio index [APRI], fibrosis-cirrhosis index [FCI], fibrosis index [FI], fibrosis-4 [FIB-4] score, fibrosis quotient [FibroQ], King, and von Willebrand factor antigen (vWF-Ag)/thrombocyte ratio [VITRO] scores) for predicting fibrosis compared with liver biopsy and to create a new score for predicting different fibrosis stages with increased accuracy...
February 28, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28243319/comparison-of-fib-4-index-and-aspartate-aminotransferase-to-platelet-ratio-index-on-carcinogenesis-in-chronic-hepatitis-b-treated-with-entecavir
#20
Hiroki Nishikawa, Norihiro Nishijima, Hirayuki Enomoto, Azusa Sakamoto, Akihiro Nasu, Hideyuki Komekado, Takashi Nishimura, Ryuichi Kita, Toru Kimura, Hiroko Iijima, Shuhei Nishiguchi, Yukio Osaki
AIMS: We sought to compare the effects of FIB-4 index and aspartate aminotransferase to platelet ratio index (APRI) on hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients undergoing entecavir (ETV) therapy. PATIENT AND METHODS: A total of 338 nucleosides analogue therapy naïve CHB patients initially treated with ETV were analyzed. The optimal cutoff points in each continuous variable were determined by receiver operating curve (ROC) analysis...
2017: Journal of Cancer
keyword
keyword
25413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"